BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines collaboration R&D Service Revenue ($M, FY16–FY22) ($M)
Form 10-Q / 10-K Collaboration Note
Latest, FY2022
46.8
Period ended Dec 31, 2022
Change on a year earlier
-12.8%
53.7 in FY2021
History
7 years
Since FY2016
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration R&D Service Revenue ($M, FY16–FY22) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 46.8 | -12.8% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 53.7 | – | Form 10-K (filed 2023-02-27) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2022-02-28) ↗ |
| FY2019 | Dec 31, 2019 | 0 | -100.0% | Form 10-K (filed 2023-02-27) ↗ |
| FY2018 | Dec 31, 2018 | 10.6 | +307.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 2.60 | +136.4% | Form 10-K (filed 2020-03-02) ↗ |
| FY2016 | Dec 31, 2016 | 1.10 | – | Form 10-K (filed 2019-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Collaboration R&D Service Revenue ($M, FY16–FY22) ($M), annual FY2016–FY2022 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rev_collab_rd_service
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.